HRA Pharma’s previous CEO and founder, Andre Ulmann, will assume the role of chairman of the company’s supervisory board.
Dr Gainer joined HRA Pharma in 2000 and has been member of its board since 2007. During this time, Dr Gainer defined, developed and managed the company’s global R&D program, notably driving its lead product candidate, ulipristal acetate as a new generation of emergency contraception under the brand name ella/ellaOne.
Dr Gainer said: “Andre has been a visionary figure not only in building a leading company in reproductive health, but in empowering millions of women to take better control of their own healthcare. I am honored to be taking over from Andre as CEO of HRA Pharma, and look forward to our continued collaboration on projects that will break new ground in untapped therapeutic needs and influence healthcare around the globe.”